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Abstract 
We aimed to assess whether whole-blood viscoelastic tests are useful to identify 
patients who are hypercoagulable and at increased risk of thromboembolism. Two 
investigators independently analyzed studies in the MEDLINE, EMBASE, and 
Cochrane controlled trial register databases to determine the ability of viscoelastic 
tests to identify a hypercoagulable state that is predictive of objectively proven 
thromboembolic events. Thirty-eight eligible studies, including 8748 patients, were 
identified and subject to meta-analysis. The majority of the studies (n=33, 87%) used 
the maximum clot strength to identify a hypercoagulable state which had a moderate 
ability to differentiate between patients who developed thromboembolic events and 
those who did not (area under the summary receiver-operating-characteristic [sROC] 
curve =0.71, 95% confidence interval [CI]: 0.65-0.76). The pooled sensitivity, 
specificity, and diagnostic odds ratio to predict thromboembolism were 55% (95%CI: 
42-67), 78% (95%CI: 68-85), and 3.7 (95%CI: 2.6-5.3), respectively. The predictive 
performance did not vary substantially between patient populations, and publication 
bias was not observed. Current evidence suggests that whole-blood viscoelastic 
tests have a moderate ability to identify a variety of patient populations with an 
increased risk of thromboembolic events, and can be considered as a useful adjunct 
to clinical judgement to stratify a patient’s risk of developing thromboembolism. 
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Introduction 
Both arterial and venous thromboembolic events are important preventable 
causes of morbidity and mortality1. According to the latest Centers for Disease 
Control and Prevention analysis, about 547,596 hospitalizations were complicated by 
venous thromboembolism each year for those aged ≥18 years in the United States2. 
About 100,000 patients died each year as a result of venous thromboembolism2,3. 
 
Anticoagulation is the current gold standard in preventing both arterial and 
venous thromboembolism. However, omission or a delay in initiating appropriate 
anticoagulant therapy or prophylaxis remains common often due to clinicians’ 
concerns about risk of bleeding4, especially in patients who have deranged 
coagulation parameters (e.g. cirrhotic patients) or those after major surgery or 
severe trauma5,6. It would be ideal if we can individualize anticoagulation for patients 
with different risks of thromboembolism, and differentiate between patients who are 
hypercoagulable and those who are at increased risk of bleeding7,8. 
 
Although numerous clinical thromboembolic prediction scores have been 
developed, their reliability and applicability in different patient populations remains 
uncertain9-11. An alternative approach is to use biomarkers or coagulation blood tests 
to identify individuals who have a hypercoagulable state. Many novel coagulation 
biomarkers have been discovered, but most of these biomarkers are expensive, not 
widely available, and consequently, far from useful as a practical thromboembolic-
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In-vitro whole-blood viscoelastic tests  including thromboelastography 
(TEG®) or rotational thromboelastometry (ROTEM®)  are widely used in many 
institutions to identify the mechanisms of bleeding in order to guide blood product 
transfusion for patients with active bleeding13. Emerging evidence suggests that an 
increase in in-vitro clot strength, demonstrated on a viscoelastic test, reflects a 
hypercoagulable state, and may be useful to identify patients who are at increased 
risk of thromboembolism14,15.  
 
We hypothesized that whole-blood viscoelastic tests can differentiate between 
patients who are hypercoagulable with an increased risk of thromboembolism and 
those who are not16,17. In this meta-analysis, we critically analyzed the literature to 
determine the ability of viscoelastic tests in identifying a hypercoagulable state that is 
predictive of objectively proven thromboembolic events. Specifically, we also 
assessed whether the commonly available viscoelastic tests have different abilities 
to predict arterial and venous thromboembolic events. 
 
Materials and Methods 
Search Strategy and Selection Criteria  
This meta-analysis was conducted according to the PRISMA and STARD 
guidelines (Appendices I and II). Two investigators independently searched the 
EMBASE (January 1980 to September 2016), MEDLINE (1966 to September 2016), 
and Cochrane Controlled Trial Register (CENTRAL) (2016, issue 9) databases using 
the following exploded Medical Subject Heading (MeSH) terms: “viscoelastic point-
of-care”, “thromboelastography”, “thromboelastometry”, “rotational 
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“venous thromboembolism”, “deep vein thrombosis”, “pulmonary embolism”, 
“prothrombotic”, or “thrombotic”. In this meta-analysis, only human studies, without 
any language restrictions, were included. The reference lists of related editorials, 
reviews and original articles identified were searched for relevant studies, and the 
web sites of the International Network of Agencies of Health Technology 
Assessment in Health Care were also searched to ensure all suitable studies were 
included. The literature search was further updated in October 2017.  
 
Although many viscoelastic tests are available, thromboelastography (TEG®) 
and rotational thromboelastometry (ROTEM®) tests are by far most widely available 
and used. As such, we have restricted our analysis to studies that used either of 
these two tests in this meta-analysis and compared their ability in predicting 
thromboembolic events. 
 
Data Extraction and Quality Assessment 
Two investigators independently examined the abstracts of the identified 
studies, followed by detail data extraction from the full texts if they were deemed 
eligible for this meta-analysis. Studies without data on thromboembolic events or 
definition for a hypercoagulable state by the whole-blood viscoelastic tests were 
excluded. The quality of the study was assessed according to the study design (e.g. 
prospective versus retrospective, cohort study versus case-control study), and 
whether assessors of the thromboembolic events were blinded to the viscoelastic 
test results. When the reported results were unclear or only available in part, we 
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Statistical Analysis and Outcomes of Interest 
Using a bivariate random-effects model18, the diagnostic odds ratio (how 
much greater the odds of developing either arterial or venous thromboembolic 
events for the people with a positive test result than for the people with a negative 
test result), sensitivity, specificity, positive and negative likelihood ratios of the 
eligible studies were pooled. We used the area under the hierarchical summary 
receiver-operating-characteristic (sROC) curve to assess the overall performance of 
the viscoelastic tests in predicting objectively proven clinical thromboembolic events 
(by ultrasound, angiography, CT imaging, or troponin level).  
 
In determining the heterogeneity of the predictive ability of the viscoelastic 
tests, we used (a) sample size and (b) prevalence of thromboembolism as a 
covariate in a meta-regression to assess whether these factors were important in 
affecting the reported results. In addition, a Threshold Analysis by Moses-Shapiro-
Littenberg model was used to assess whether the cut-points used to define 
hypercoagulability were related to the differences in the reported diagnostic odds 
ratios.  
 
In addition, we conducted a number of subgroup and sensitivity analyses to 
explore possible reasons for heterogeneity. These included (a) restricting our 
analysis to only higher quality prospective studies in which assessors of the 
thromboembolic events were blinded to the test results, (b) restricting our analyses 
to specific patient populations, (c) comparing the predictive performance of the two 
viscoelastic tests (TEG® vs ROTEM®), and (d) assessing whether the viscoelastic 
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used a modified funnel plot technique, recommended by Deeks et al., to assess 
publication bias19.  
 
All analyses were performed by Open Meta-Analyst20, Meta-disc (version 
1.4)21, and SPSS for Windows (version 24.0, IBM, 2016), and a p value <0.05 was 





Search results  
Of the 4743 studies identified in the databases, 38 studies from 14 countries, 
including 8748 patients in a variety of clinical settings, met the inclusion criteria and 
were subject to meta-analysis (Figure 1)22-59. A list of the studies excluded and the 
reasons for their exclusion are summarized in Appendix III. 
 
Of the 38 studies included in the final analysis, 25 were prospective studies 
and most were cohort studies in which the viscoelastic test was performed before the 
thromboembolic events  (n=32, 84%). As for the case-control studies, the 
viscoelastic test was performed subsequent to an interval after cessation of systemic 
anticoagulation. Blinding of the assessment of the thromboembolic events to the 
viscoelastic results was used in five studies (13%) including a total of 1599 patients. 
Twenty-seven studies used the thromboelastography (TEG®) and eleven studies 
used the rotational thromboelastometry (ROTEM®) to predict thromboembolic 
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(maximum amplitude on the TEG® or maximum clot firmness on the ROTEM®), 
either alone or as part of an index, to define a hypercoagulable state. The 
characteristics of the included studies, including the diagnostic criteria used to define 
a hypercoagulable state, the prevalence of thromboembolic events and type of 
patients assessed, are described in detail in Table 1. 
 
Ability of viscoelastic tests to predict thromboembolic events 
The overall ability of a hypercoagulable state, identified by a viscoelastic test, 
to predict thromboembolic events was moderate (the area under the sROC curve 
was 0.71, 95% confidence interval [CI]: 0.65-0.76) (Figure 2). The pooled sensitivity, 
specificity, and diagnostic odds ratio of whole-blood viscoelastic tests to predict 
thromboembolic events were 55% (95%CI: 42-67), 78% (95%CI: 69-85), and 3.7 
(95%CI: 2.6-5.3), respectively (Figure 3). The negative and positive likelihood ratios 
of the viscoelastic tests to predict thromboembolic events in each study and the 
overall pooled likelihood ratios are summarized in Appendix IV. 
 
Difference between predicting venous and arterial thromboembolic events 
Nineteen and five studies assessed the viscoelastic test’s ability to predict 
solely deep vein thrombosis (DVT) / pulmonary embolism (PE) and arterial 
thromboembolic events, respectively. Viscoelastic tests appeared to have a better 
ability in predicting arterial thromboembolic events (sROC 0.74, 95%CI: 0.61-0.87; 
pooled diagnostic odds ratio 6.6, 95%CI: 2.6-17.2; sensitivity 66%, 95%CI: 57-75; 
specificity 71%, 95%CI: 67-75) than DVT or PE (sROC 0.69, 95%CI: 0.60-0.78; 
pooled diagnostic odds ratio 3.3, 95%CI: 2.0-5.6; sensitivity 32%, 95%CI: 28-36; 
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ability to predict portal vein thrombosis in patients with cirrhosis (n=4; sROC 0.75, 
95%CI: 0.61-0.88; pooled diagnostic odds ratio 4.4, 95%CI: 1.7-11.1; sensitivity 
21%, 95%CI: 14-31; specificity 78%, 95%CI: 72-83). 
 
Effects of sample size and prevalence of thromboembolic events on performance of 
the viscoelastic tests 
The sample size (n=16 to 2067) and prevalence (2.2% to 45% for prospective 
cohort studies) of the included studies varied substantially (Table 1), but there was 
no significant association between either the sample size (slope of the regression 
line =0, 95%CI: -0.001 to 0.001; P=0.427) or prevalence of the thromboembolic 
events (slope of the regression line =0.008, 95%CI: -0.018 to 0.034; P=0.536) and 
the predictive ability of the viscoelastic tests (Appendices V and VI, respectively).  
 
Sensitivity analyses, Threshold Analysis and publication bias 
Overall, lower quality studies tended to yield more favourable results than 
higher quality studies (prospective: n=25; sROC 0.70, 95%CI: 0.63-0.77 vs 
retrospective: n=13; sROC 0.73, 95%CI: 0.64-0.82 and cohort studies: n=32; sROC 
0.70, 95%CI: 0.64-0.75 vs case-control study: n=6; sROC 0.83, 95%CI: 0.61-0.99). 
After restricting the analysis only to the highest quality studies (that were both 
prospective and blinded; n=5 with 1599 patients), the pooled diagnostic odds ratio 
(3.4, 95%CI: 1.5-7.8), sensitivity (48%, 95%CI: 23-74), and specificity (79%, 95%CI: 
44-95) remained similar to the main results.  
Compared to TEG®, ROTEM® had a better ability to predict thromboembolic 
events (sROC and pooled diagnostic odds ratio 0.69 and 3.3 vs 0.78 and 6.3, 
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The thresholds used to define hypercoagulability were not significantly 
associated with the reported diagnostic odds ratios of the viscoelastic tests 
(P=0.874), and the predictive performance of the tests did not vary substantially 
between different patient populations (cancer patients: sROC 0.77, trauma patients: 
sROC 0.66, perioperative patients: sROC 0.69, critically ill patients: sROC 0.77). 
Finally, publication bias was also not observed (Figure 4).  
 
Discussion 
This meta-analysis showed that whole-blood viscoelastic tests had a 
moderate ability to discriminate between patients who developed thromboembolism 
and those who did not in a variety of patient populations. These results are clinically 
relevant and require further discussion. 
 
First, evidence suggests that whole-blood viscoelastic tests have the potential 
to inform the clinicians about the mechanisms of bleeding over and above the 
information provided by standard coagulation blood tests14,60. Because a viscoelastic 
test assesses the clotting process of whole blood, including platelets, it has a 
potential to reflect bleeding or thrombotic tendency that is not measurable by 
activated partial thromboplastin time or prothrombin time, as both tests only use 
platelet-poor plasma60. Our results suggested that a viscoelastic hypercoagulable 
state is associated with an increased risk of thromboembolism, a 3.7-fold higher odd, 
compared to those without a hypercoagulable state. And as this was a diagnostic 
odds ratio, it would not be affected by the prevalence of the thromboembolism61. 
Indeed, our meta-regression did not show any association between the prevalence 
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studies. sROC is also known to be robust to study heterogeneity62, and together with 
the consistency in the results of  our multiple sensitivity analyses, the findings of this 
study are likely to be generalizable to a variety of patient cohorts with different 
prevalence of thromboembolism.  
 
The relatively high specificity (78%) of a viscoelastic hypercoagulable state 
would suggest that such result has a low false positive rate in identifying patients 
who would develop thromboembolism. Withholding anticoagulant prophylaxis for 
patients with a hypercoagulable viscoelastic test result would thus be not advisable, 
especially if the patients are also judged to be at high risk of developing 
thromboembolism, based on either clinical ground (e.g. atrial fibrillation, 
immobilization, and recent surgery) or thrombotic risk scores17. 
 
Second, the relatively low sensitivity (55%) of a viscoelastic hypercoagulable 
result suggested that not all patients who developed thromboembolic events could 
be identified by this test. As such, a non-hypercoagulable viscoelastic test result 
does not imply that a patient would not develop subsequent arterial or venous 
thromboembolism. Any decision to initiate (or withhold) anticoagulant prophylaxis 
must circumspect the benefits of reducing thromboembolic events and its harms on 
increased risk of bleeding, using other clinical and laboratory information. There are, 
at least, a few possible reasons why viscoelastic tests will have a low sensitivity in 
predicting thromboembolic events. Whole-blood viscoelastic tests use thrombin 
related activators to activate the clotting process and are not sensitive to measure 
platelet activity in some diseases or drug effects (e.g. ADP receptor or 
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all pathogenic mechanisms of thromboembolism, including stasis in blood flow, 
vessel injury, and endothelial activation (e.g. thrombotic microangiopathy)63. In 
addition, the techniques and activators used to perform the viscoelastic test may also 
be important. Our results suggest that ROTEM® – often a laboratory-based test – 
appeared to outperform the point-of-care TEG®, in predicting thromboembolism. 
 
Finally, we would like to acknowledge the limitations of this meta-analysis. 
Although we had included a large number of studies involving a variety of patient 
populations, the total number of patients analysed was still limited, and hence, the 
overall pooled results were imprecise. The included studies also used different 
follow-up durations after the test to detect thromboembolic events, which could 
introduce heterogeneity because hypercoagulability due to most non-genetic causes 
may change, in one way or another, with time (e.g. infection). We also noted that 
none of the included studies assessed the whole-blood viscoelastic tests in 
conjunction with other prothrombotic biomarkers to predict thromboembolic 
events12,13. Whether viscoelastic tests can supplement other coagulation biomarkers 
in predicting thromboembolism remains uncertain, but this merits further 
investigation. 
 
In summary, maximum clot strength on a viscoelastic tracing, either alone or 
in combination with other parameters, has a modest ability to identify individuals who 
are hypercoagulable and at increased risk of subsequent either arterial or venous 
thromboembolic events in a variety of patient populations regardless of the 
underlying prevalence of thromboembolism. A non-hypercoagulable viscoelastic test 
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thromboembolism. With this caveat in mind, viscoelastic tests can be considered as 
a useful adjunct to clinical judgement to stratify a patient’s risk of developing 
thromboembolism, in addition to its more established role of guiding blood product 
transfusion in critical bleeding14,60. 
 




We would sincerely like to thank Drs B. A. Cotton, O. Koçak, M. S. Park, M. Senzolo, 
P. Simioni, L. Spiezia, and A. Zanetto for providing additional data from their original 
studies for this meta-analysis.  
 
Figure legends 
Figure 1. Flow chart showing the inclusion and exclusion of studies for the meta-
analysis. 
Figure 2. Area under the summary receiver-operating-characteristic (sROC) curve of 
38 studies summarizing the ability of a hypercoagulable state to predict clinical 
thromboembolic events was 0.71 (95%CI: 0.65-0.76) using a bivariate random-
effects model. Size of the marker is directly proportional to the size of the study in 
the sROC graph. 
Figure 3. Forest plot showing the pooled diagnostic odds ratio (3.7, 95%CI 2.6-5.3) 
of a hypercoagulable state to predict clinical thromboembolic events. 
Figure 4. The funnel plot, with the regression line in dash line (P=0.984), shows no 
obvious publication bias. ESS, effective sample size. ESS= (4xn1xn2)/(n1+n2) 
where n1 = number of patients with thromboembolism and n2= number of patients 
without thromboembolism in the study. Pooled diagnostic odds ratio from 38 studies 












This article is protected by copyright. All rights reserved. 
Appendices Index 
Appendix I   PRISMA Guidelines 
Appendix II   STARD Guidelines 
Appendix III   List of excluded studies 
Appendix IV   Negative and positive likelihood ratios 
Appendix V   Meta-regression: Sample size and diagnostic odds ratio 
Appendix VI  Meta-regression: Prevalence of thromboembolism and 
diagnostic odds ratio 
 
References 
1. Wendelboe AM, McCumber M, Hylek EM, et al. Global public awareness of 
venous thromboembolism. J Thromb Haemost. 2015;13:1365-1371. 
2. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in 
adult hospitalizations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep. 
2012;61:401-444. 
3. US Department of Health and Human Services. The Surgeon General's call to 
action to prevent deep vein thrombosis and pulmonary embolism. Office of the 
Surgeon General (US); National Heart, Lung, and Blood Institute (US). Rockville 
(MD): Office of the Surgeon General (US); 2008. Available at 
https://www.ncbi.nlm.nih.gov/books/NBK44178/ 
4. Millar JA, Gee AL. Estimation of clinical and economic effects of prophylaxis 
against venous thromboembolism in medical patients, including the effect of 
targeting patients at high-risk. Intern Med J. 2016;46:315-324. 
5. Ginzburg E, Dujardin F. Physicians' perceptions of the definition of major 
bleeding in major orthopedic surgery: results of an international survey. J Thromb 
Thrombolysis. 2011;31:188-195.  
6. Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality 










This article is protected by copyright. All rights reserved. 
7. La Regina M, Orlandini F, Marchini F, et al. Combined assessment of thrombotic 
and haemorrhagic risk in acute medical patients. Thromb Haemost. 
2016;115:392-398. 
8. Welsby I, Ortel TL. Is it time for individualized thromboprophylaxis regimens in 
the ICU? Crit Care Med. 2015;43:500-501. 
9. Swanson E. Caprini Scores, Risk Stratification, and Rivaroxaban in Plastic 
Surgery: Time to Reconsider Our Strategy. Plast Reconstr Surg Glob Open. 
2016;4:e733. 
10. Ho KM, Rao S, Rittenhouse KJ, et al. Use of the Trauma Embolic Scoring 
System (TESS) to predict symptomatic deep vein thrombosis and fatal and non-
fatal pulmonary embolism in severely injured patients. Anaesth Intensive Care. 
2014;42:709-714. 
11. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the 
identification of hospitalized medical patients at risk for venous 
thromboembolism: the Padua Prediction Score. J Thromb Haemost. 
2010;8:2450-2457. 
12. Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb 
Vasc Biol. 2009;29:332-336.  
13. Bruzelius M, Iglesias MJ, Hong MG, et al. PDGFB, a new candidate plasma 
biomarker for venous thromboembolism: results from the VEREMA affinity 
proteomics study. Blood. 2016;128:e59-e66. 
14. Whiting P, Al M, Westwood M, et al. Viscoelastic point-of-care testing to assist 
with the diagnosis, management and monitoring of haemostasis: a systematic 










This article is protected by copyright. All rights reserved. 
15. Harahsheh Y, Ho KM. Viscoelastic point-of-care testing to guide transfusion and 
antithrombotic therapy in perioperative and critically ill patients: are all 
parameters created equal? Anaesth Intensive Care. 2016;44:11-13. 
16. Dai Y, Lee A, Critchley LA, et al. Does thromboelastography predict 
postoperative thromboembolic events? A systematic review of the literature. 
Anesth Analg. 2009;108:734-742. 
17. Ay C, Pabinger I. VTE risk assessment in cancer. Who needs prophylaxis and 
who does not? Hamostaseologie. 2015;35:319-324. 
18. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and 
specificity produces informative summary measures in diagnostic reviews. J Clin 
Epidemiol. 2005;58:982-990. 
19. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and 
other sample size effects in systematic reviews of diagnostic test accuracy was 
assessed. J Clin Epidemiol. 2005;58:882-893. 
20. Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of 
binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80. 
21. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of 
test accuracy data. BMC Med Res Methodol. 2006;6:31. 
22. Zheng Q, Bai J, Fu S, et al. Association between thrombelastography system and 
vascular obstructions and hemorrhage: a two-year follow-up study of elderly 
Chinese patients. Ann Clin Lab Sci. 2014;44:194-201. 
23. Gary JL, Schneider PS, Galpin M, et al. Can thrombelastography predict venous 











This article is protected by copyright. All rights reserved. 
24. Pommerening MJ, Rahbar E, Minei K, et al. Splenectomy is associated with 
hypercoagulable thrombelastography values and increased risk of 
thromboembolism. Surgery. 2015;158:618-626. 
25. Parameswaran A, Krishnamoorthy VP, Oommen AT, et al. Is pre-operative 
assessment of coagulation profile with Thrombelastography (TEG) useful in 
predicting venous thromboembolism (VTE) following orthopaedic surgery? J Clin 
Orthop Trauma. 2016;7:225-229. 
26. Gurbel PA, Bliden KP, Kreutz RP, et al. The link between heightened 
thrombogenicity and inflammation: pre-procedure characterization of the patient 
at high risk for recurrent events after stenting. Platelets. 2009;20:97-104. 
27. Schreiber MA, Differding J, Thorborg P, et al. Hypercoagulability is most 
prevalent early after injury and in female patients. J Trauma. 2005;58:475-480. 
28. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent 
events post-stenting: results of the PREPARE POST-STENTING Study. J Am 
Coll Cardiol. 2005;46:1820-1826. 
29. Rafiq S, Johansson PI, Ostrowski SR, et al. Hypercoagulability in patients 
undergoing coronary artery bypass grafting: prevalence, patient characteristics 
and postoperative outcome. Eur J Cardiothorac Surg. 2012;41:550-555. 
30. Tartamella F, Vassallo MC, Berlot G, et al. Thromboelastographic predictors of 
venous thromboembolic events in critically ill patients: are we missing 
something? Blood Coagul Fibrinolysis. 2016;27:804-811. 
31. Allen CJ, Murray CR, Meizoso JP, et al. Coagulation Profile Changes Due to 
Thromboprophylaxis and Platelets in Trauma Patients at High-Risk for Venous 










This article is protected by copyright. All rights reserved. 
32. Zacho M, Rafiq S, Kelbæk H, et al. Hypercoagulability in relation to coronary 
artery bypass graft patency and clinical outcome. Scand Cardiovasc J. 
2013;47:104-108. 
33. Hvitfeldt Poulsen L, Christiansen K, Sørensen B, et al. Whole blood 
thrombelastographic coagulation profiles using minimal tissue factor activation 
can display hypercoagulation in thrombosis-prone patients. Scand J Clin Lab 
Invest. 2006;66:329-336. 
34. Ho KM, Duff OC. Predictors of an increased in vitro thrombotic and bleeding 
tendency in critically ill trauma and non-trauma patients. Anaesth Intensive Care. 
2015;43:317-322. 
35. Toukh M, Siemens DR, Black A, et al. Thromboelastography identifies 
hypercoagulablilty and predicts thromboembolic complications in patients with 
prostate cancer. Thromb Res. 2014;133:88-95. 
36. Cotton BA, Minei KM, Radwan ZA, et al. Admission rapid thrombelastography 
predicts development of pulmonary embolism in trauma patients. J Trauma Acute 
Care Surg. 2012;72:1470-5. 
37. Wen YR, Ho WY, Sun WZ, et al. Thromboelastographic study of thrombosis in 
the implantable central venous access device. Acta Anaesthesiol Sin. 
1997;35:223-228. 
38. Welsh KJ, Padilla A, Dasgupta A, et al. Thromboelastography is a suboptimal test 
for determination of the underlying cause of bleeding associated with 











This article is protected by copyright. All rights reserved. 
39. Krzanicki D, Sugavanam A, Mallett S. Intraoperative hypercoagulability during 
liver transplantation as demonstrated by thromboelastography. Liver Transpl. 
2013;19:852-861. 
40. McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum 
amplitude predicts postoperative thrombotic complications including myocardial 
infarction. Anesth Analg. 2005;100:1576-1583. 
41. Abrahams JM, Torchia MB, McGarvey M, et al. Perioperative assessment of 
coagulability in neurosurgical patients using thromboelastography. Surg Neurol. 
2002;58:5-11. 
42. Cerutti E, Stratta C, Romagnoli R, et al. Thromboelastogram monitoring in the 
perioperative period of hepatectomy for adult living liver donation. Liver Transpl. 
2004;10:289-294. 
43. O'Donnell J, Riddell A, Owens D, et al. Role of the Thrombelastograph as an 
adjunctive test in thrombophilia screening. Blood Coagul Fibrinolysis. 
2004;15:207-211. 
44. Kashuk JL, Moore EE, Sabel A, et al. Rapid thrombelastography (r-TEG) 
identifies hypercoagulability and predicts thromboembolic events in surgical 
patients. Surgery. 2009;146:764-772. 
45. Kapoor S, Pal S, Sahni P, et al. Thromboelastographic evaluation of coagulation 
in patients with extrahepatic portal vein thrombosis and non-cirrhotic portal 
fibrosis: a pilot study. J Gastroenterol Hepatol. 2009;24:992-997. 
46. Koopman K, Uyttenboogaart M, Hendriks HG, et al. Thromboelastography in 










This article is protected by copyright. All rights reserved. 
47. Traverso CI, Arcelus JI. Prospective assessment of the risk of deep vein 
thrombosis in elective abdominal surgery. Predictive role of thromboelastography. 
Thromb Haemorrh Disord. 1993;7:9-15. 
48. Dumitrescu G, Januszkiewicz A, Ågren A, et al. The temporal pattern of 
postoperative coagulation status in patients undergoing major liver surgery. 
Thromb Res. 2015;136:402-407. 
49. Hincker A, Feit J, Sladen RN, et al. Rotational thromboelastometry predicts 
thromboembolic complications after major non-cardiac surgery. Crit Care. 
2014;18:549. 
50. Kolbenschlag J, Daigeler A, Lauer S, et al. Can rotational thromboelastometry 
predict thrombotic complications in reconstructive microsurgery? Microsurgery. 
2014;34:253-260. 
51. Spiezia L, Marchioro P, Radu C, et al. Whole blood coagulation assessment 
using rotation thrombelastogram thromboelastometry in patients with acute deep 
vein thrombosis. Blood Coagul Fibrinolysis. 2008;19:355-360. 
52. Davies NA, Harrison NK, Sabra A, et al. Application of ROTEM to assess 
hypercoagulability in patients with lung cancer. Thromb Res. 2015;135:1075-
1080. 
53. Van Haren RM, Valle EJ, Thorson CM, et al. Long-term coagulation changes 
after resection of thoracoabdominal malignancies. J Am Coll Surg. 2014;218:846-
854. 
54. Koçak O, Yarar C, Turhan AB, et al. Evaluation of hypercoagulability state in 











This article is protected by copyright. All rights reserved. 
55. Rossetto V, Spiezia L, Senzolo M, et al. Whole blood rotation 
thromboelastometry (ROTEM®) profiles in subjects with non-neoplastic portal 
vein thrombosis. Thromb Res. 2013;132:e131-e134. 
56. Taura P, Rivas E, Martinez-Palli G, et al. Clinical markers of the hypercoagulable 
state by rotational thrombelastometry in obese patients submitted to bariatric 
surgery. Surg Endosc. 2014;28:543-551. 
57. Liu J, Wang N, Chen Y, et al. Thrombelastography coagulation index may be a 
predictor of venous thromboembolism in gynecological oncology patients. J 
Obstet Gynaecol Res. 2017;43:202-210. 
58. Thorson CM, Van Haren RM, Ryan ML, et al. Pre-existing hypercoagulability in 
patients undergoing potentially curative cancer resection. Surgery. 2014;155:134-
144. 
59. Zanetto A, Senzolo M, Vitale A, et al. Thromboelastometry hypercoagulable 
profiles and portal vein thrombosis in cirrhotic patients with hepatocellular 
carninoma. Dig Liver Dis. 2017;49:440-445. 
60. Ho KM, Pavey W. Applying the cell-based coagulation model in the management 
of critical bleeding. Anaesth Intensive Care. 2017;45:166-176. 
61. Šimundić AM. Measures of Diagnostic Accuracy: Basic Definitions. EJIFCC. 
2009;19:203-211. 
62. Walter SD. Properties of the summary receiver operating characteristic (SROC) 
curve for diagnostic test data. Stat Med. 2002;21:1237-1256. 
63. Harahsheh Y, Ho KM. Thromboelastometry and thromboelastography failed to 












This article is protected by copyright. All rights reserved. 






Type of patients Whole-blood 
viscoelastic 

















Hospitalized patients >65 
years old  
MA on TEG >69mm Retrospective, 
cohort 
No 20.6% (myocardial 
infarction, ischemic 




Patients with severe 
extremity trauma  
MA on TEG >72mm Retrospective, 
cohort 




Adult trauma patients MA or angle on TEG > 
upper limit of normal 
Prospective, cohort Yes 6.4% (myocardial 
infarction, ischemic 




Patient with hip / knee 
fracture or arthritis for 
arthroplasty 












Adult trauma patients R-time <3.7 minutes 
on TEG 













coronary artery bypass 
grafting 
MA on TEG >69mm Prospective, cohort Yes 10.3% (myocardial 
infarction, ischemic 
stroke) 
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2016, n=57, 
Italy30 
(MA x α-angle/R-time) 
>10.6 on TEG 
Allen, 2015, 
n=74, USA31 
Adult trauma patients Either R-time >9 
minutes, α-angle >580, 
or MA >64mm on TEG 





coronary artery bypass 
grafting 










Patients referred to 
thrombophilia investigation 
after an episode of 
thromboembolism and 
healthy controls 
MaxVel values on 
ROTEM outside 2 
standard deviations 




No 13.3% (based on the 
case to control ratio, 





Critically ill adult patients MA and α-angle on 
TEG >72mm and 740, 
respectively 




Patients with prostatic 
cancer and controls 
Three or more of the 
followings, R-time, K-
time, α-angle, MA or 
coagulation index on 
TEG, were outside 
average +/- one 
standard deviation of 
the controls  
Prospective, cohort No 25% (among those with 
prostatic cancer, 20% if 
controls were included, 





Adult trauma patients MA on TEG >72mm Retrospective, 
cohort 





R-time, α-angle and 
MA on TEG <6 
Prospective, cohort No 14.5% (thrombosis of 










This article is protected by copyright. All rights reserved. 







with bleeding requiring 
hematology consultation 












on TEG >7100 
Retrospective, 
cohort 





Patients undergoing a wide 
variety of surgical 
procedures 
MA on TEG >68mm Prospective, cohort Yes 39.6% (DVT, PE, 







Thrombotic index (= -
0.1227 x R-time + 
0.0092 x K-time + 
0.1655 x MA – 0.0241 
x α-angle – 0.5022) on 
TEG >/=3.57 
Prospective, cohort No 2.2% (DVT) 
Cerutti, 2004, 
n=10, Italy42 
Patients undergoing donor 
liver hepatectomy 
Coagulation index (= -
0.3258 x R-time – 
0.1886 x K-time + 
0.1224 x MA + 0.0759 
x α-angle – 7.7922) on 
the TEG >3 
Retrospective, 
cohort 




Patients with a personal or 
family history of thrombotic 
event 












No 10.5% (DVT, PE, 
mesenteric arterial and 
venous thrombosis) 
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n=49, India45 portal vein thrombosis 
(cases) and non-cirrhotic 
portal fibrosis (controls) 
0.1227 x R-time + 
0.0092 x K-time + 
0.1655 x MA – 0.0241 
x α-angle – 0.5022) on 
TEG >2.5 






Patients with cerebral 
venous thrombosis (cases) 
and without thrombosis 
(controls)  
One or more of the 
followings, R-time, K-
time, α-angle, or MA, 
were outside the 
reference range 
towards a 




No 34.2% (based on but the 







elective abdominal surgery 
> 1hr 




Patients undergoing major 
liver surgery 
MCF on at least 1 of 3 
ROTEM tests 
(INTEM/EXTEM/FIBTE
M) > reference value 
Prospective, cohort No 12.5% (PE) 
Hincker, 2014, 
n=313, USA49 
Patients undergoing major 
non-cardiac surgery 
MCF on at least 1 of 3 
ROTEM tests 
(INTEM/EXTEM/FIBTE
M) > reference value 
Prospective, cohort Yes 3.2% (DVT, PE, arterial 








MCF on INTEM or 
EXTEM ROTEM 








Patients with acute DVT 
(cases) and healthy age-
matched controls 





No 42.9% (based on the 




Patients with lung cancer 
(cases) and age-matched 
Either with a shortened 
CFT (INTEM>100s or 
Prospective, cohort No 14.9% (among the lung 
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controls EXTEM >148s) or an 
increase in MCF on 
ROTEM >72mm 
when healthy individuals 








One or more of the 
followings, clotting 




Prospective, cohort No 5.8% (DVT or PE) 
Koçak, 2016, 
n=39, Turkey54 
Patients with perinatal 
arterial ischemic stroke 
(cases) and healthy 
controls 
One or more of the 
followings, clotting 






No 51.3% (based on the 






neoplastic portal vein 
thrombosis (cases) and 
healthy volunteers or 
cirrhotic patients (controls) 
One or more of the 
followings, clotting 
time, CFT, MCF or the 






No 50% (based on the case 





Patients with obesity 
undergoing laparoscopic 
bariatric surgery 
G index >/= 11 
dynes/cm2 




Patients with gynecological 
oncology condition 
Coagulation index (-
0.6516 x R-time – 
0.3772 x K-time + 
0.1224 x MA + 0.0759 




No 10.4% (DVT or PE) 


















(CT, CFT, MCF in 
EXTEM or INTEM, 







Patients with cirrhosis, with 
and without hepatocellular 
carcinoma 
At least 1 
hypercoagulable 
parameter (CT, CFT or 
MCF) on 1 or more of 





No 18.4% (portal vein 
thrombosis) 
CFT = clot formation time (to 20mm above baseline on ROTEM®); CT = clotting time; DVT = deep vein thrombosis; K- time = clot 
formation time to 20mm above baseline on TEG®; PE = pulmonary embolism; MA = maximum amplitude on the TEG®; MCF = 
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